In a new note to investors yesterday, an analyst has provided a rating update for the Materials sector company, OrganiGram Holdings (TSXV: OGI). The company received a Buy rating from GMP FirstEnergy’s analyst Martin Landry, with a C$8 price target.

Landry has an average return of 30.8% when recommending OrganiGram Holdings.

According to TipRanks.com, Landry is ranked #92 out of 4840 analysts.

Read also: Crude Oil: Sell Now, Buy Later

OrganiGram Holdings has an analyst consensus of Strong Buy, with a price target consensus of C$7, representing a 40.6% upside. In a report issued on July 27, Echelon Wealth Partners also initiated coverage with a Buy rating on the stock with a C$7 price target.

.

The company has a one-year high of C$5.93 and a one-year low of C$2.11. Currently, OrganiGram Holdings has an average volume of 760.5K.

OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. Through Organigram Inc., its main focus is on the production of condition specific medical marijuana for patients in Canada. The company was founded on August 22, 2014 and is headquartered in Moncton, Canada.

The company’s shares closed on Tuesday at C$4.98.